Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy.

Livingston EG, Cohn SE, Yang Y, Watts HD, Bardeguez AD, Jones TB, Smith LM, Umbleja T, McComsey GA.

Obstet Gynecol. 2007 Aug;110(2 Pt 1):391-7.

PMID:
17666616
2.

Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy.

Melvin AJ, Kang M, Hitti J, Livingston E, Cohn SE, Stocker V, Ross AC, Watts H, McComsey GA.

Antivir Ther. 2008;13(3):349-55.

PMID:
18572747
3.

Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, O'Sullivan MJ, Scott G, Stek AM, Wara D, Bulterys M.

N Engl J Med. 2002 Jun 13;346(24):1863-70.

4.

Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.

Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, Casteleyn S, Feiterna-Sperling C, Groeger S, Zaknun D; Multicenter Interdisciplinary Study Group Germany/Austria.

HIV Med. 2008 Jan;9(1):6-13. doi: 10.1111/j.1468-1293.2008.00520.x.

5.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112
6.

Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003.

Martí C, Peña JM, Bates I, Madero R, de José I, Pallardo LF, Arribas JR, Gonzalez-Garcia J, Gonzalez A, Vazquez JJ.

Acta Obstet Gynecol Scand. 2007;86(4):409-15.

PMID:
17486461
7.

Lack of effect on prematurity, birth weight, and infant growth from exposure to protease inhibitors in utero and after birth.

Carceller A, Ferreira E, Alloul S, Lapointe N.

Pharmacotherapy. 2009 Nov;29(11):1289-96. doi: 10.1592/phco.29.11.1289.

PMID:
19857146
8.

Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women.

McGowan JP, Crane M, Wiznia AA, Blum S.

Obstet Gynecol. 1999 Nov;94(5 Pt 1):641-6.

PMID:
10546703
9.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
10.

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG; Pediatric Spectrum of HIV Disease Consortium.

Pediatrics. 2007 Apr;119(4):e900-6. Epub 2007 Mar 12.

PMID:
17353299
11.

Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy.

Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC.

Pediatr Infect Dis J. 2003 Sep;22(9):782-9.

PMID:
14506368
12.

Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.

Szyld EG, Warley EM, Freimanis L, Gonin R, Cahn PE, Calvet GA, Duarte G, Melo VH, Read JS; NISDI Perinatal Study Group.

AIDS. 2006 Nov 28;20(18):2345-53.

PMID:
17117021
13.

The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery.

Boer K, Nellen JF, Patel D, Timmermans S, Tempelman C, Wibaut M, Sluman MA, van der Ende ME, Godfried MH.

BJOG. 2007 Feb;114(2):148-55.

14.
15.

Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.

Floris-Moore M, Howard AA, Lo Y, Arnsten JH, Santoro N, Schoenbaum EE.

HIV Med. 2006 Oct;7(7):421-30.

16.

Protease inhibitor use in 233 pregnancies.

Morris AB, Dobles AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, Keller J, Garb J.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):30-3.

PMID:
16123678
17.

Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.

Chmait R, Franklin P, Spector SA, Hull AD.

J Perinatol. 2002 Jul-Aug;22(5):370-3.

18.

Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy.

Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, Landesman S, Zorrilla C, Thompson B; Women and Infants Transmission Study.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):449-73.

PMID:
15764963
19.

Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.

Hitti J, Andersen J, McComsey G, Liu T, Melvin A, Smith L, Stek A, Aberg J, Hull A, Alston-Smith B, Watts DH, Livingston E; AIDS Clinical Trials Group 5084 Study Team.

Am J Obstet Gynecol. 2007 Apr;196(4):331.e1-7.

PMID:
17403409
20.

Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.

Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.

AIDS. 2008 Sep 12;22(14):1815-20. doi: 10.1097/QAD.0b013e32830b8ab9.

PMID:
18753864

Supplemental Content

Support Center